Format

Send to

Choose Destination
Clin Lung Cancer. 2018 Jan;19(1):35-41. doi: 10.1016/j.cllc.2017.06.010. Epub 2017 Jul 6.

Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.

Author information

1
Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Department of Pathology, Antwerp University Hospital, Antwerp, Belgium; Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
2
Department of Pneumology, AZ Herentals, Herentals, Belgium.
3
Department of Pathology, AZ Herentals, Herentals, Belgium; Laboratory of Cell Biology and Histology, University of Antwerp, Antwerp, Belgium.
4
Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy.
5
Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Department of Pneumology, AZ Maria Middelares, Ghent, Belgium.
6
Phase I - Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium.
7
Department of Medicine, University of California Davis Cancer Center, Sacramento, CA.
8
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy.
9
Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
10
Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Department of Pathology, Antwerp University Hospital, Antwerp, Belgium.
11
Center for Oncological Research, University of Antwerp, Antwerp, Belgium; Phase I - Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Antwerp, Belgium. Electronic address: Christian.rolfo@uza.be.

Abstract

Several oncogenic drivers have been identified in non-small cell lung cancer. Targeted therapies for these aberrations have already been successfully developed and implemented in clinical practice. Owing to improved sensitivity in genetic testing, more and more tumors with multiple driver mutations are identified, resulting in dilemmas for treating physicians whether and which targeted therapy to use. In this case series, we provide an overview of patients with intrinsic double mutations in oncogenic drivers and their reported response to targeted therapies, with a focus on epidermal growth factor receptor, anaplastic lymphoma kinase, cMET, and Kirsten rat sarcoma viral oncogene. We also include an unpublished case report on a patient with an epidermal growth factor receptor L858R and cMET exon 14 skipping.

KEYWORDS:

ALK; EGFR; KRAS; Non–small cell lung cancer; cMET

PMID:
28757336
DOI:
10.1016/j.cllc.2017.06.010

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center